Menu
Search
|

Menu

Close
X

Intercept Pharmaceuticals Inc ICPT.OQ (NASDAQ Stock Exchange Global Select Market)

96.00 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 96.00
Open --
Volume --
3m Avg Volume 250,376
Today’s High --
Today’s Low --
52 Week High 135.59
52 Week Low 51.11
Shares Outstanding (mil) 25.10
Market Capitalization (mil) 1,754.86
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 16 analysts

KEY STATS

Revenue (mm, USD)
FY18
36
FY17
131
FY16
25
FY15
3
EPS (USD)
FY18
-3.224
FY17
-14.382
FY16
-16.741
FY15
-9.496
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
24.74
5.73
Price to Book (MRQ)
vs sector
10.34
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
205.28
16.72
LT Debt to Equity (MRQ)
vs sector
205.28
12.39
Return on Investment (TTM)
vs sector
-81.11
14.61
Return on Equity (TTM)
vs sector
-131.43
16.34

EXECUTIVE LEADERSHIP

Paolo Fundaro
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Mark Pruzanski
President, Chief Executive Officer, Director, Since 2002
Salary: $675,000.00
Bonus: $401,625.00
Sandip Kapadia
Chief Financial Officer, Treasurer, Since 2016
Salary: $425,000.00
Bonus: $188,594.00
Lisa Bright
President, International, Since 2016
Salary: $367,280.00
Bonus: $135,680.00
Jerome Durso
Chief Operating Officer, Since 2017
Salary: $441,333.00
Bonus: $260,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10 Hudson Yards Fl 37
NEW YORK   NY   10001-2160

Phone: +1646.7471000

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

SPONSORED STORIES